Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.47 |
| ▸ | CNR2 | P34972 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823416 | 0.87 | CNR1 (0.43) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823459 | 0.85 | MEN1 (0.58) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL823432 | 0.84 | CNR1 (0.41) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823464 | 0.84 | CNR1 (0.44) | CNR1CNR2MEN1KMT2APPARG | |
| SCHEMBL823468 | 0.84 | OPRK1 (0.46) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823489 | 0.83 | KMT2A (0.47) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823474 | 0.83 | KMT2A (0.48) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823413 | 0.82 | ENPP2 (0.42) | CNR1CNR2MEN1KMT2ATSHR | |
| SCHEMBL823472 | 0.82 | CNR2 (0.43) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL823440 | 0.82 | OPRM1 (0.41) | CNR1CNR2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| EP-2114903-B1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| WO-2008077188-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | CNR1 1068/4885CNR2 1516/4885MEN1 1774/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | CNR1 1068/4885CNR2 1516/4885MEN1 1774/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | CNR1 1068/4885CNR2 1516/4885MEN1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.